天新药业 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	2.2B	1.9B	2.3B	2.5B	2.3B
Revenue Growth %	17.4%	-18.4%	-8.6%	9.5%	--
Total Revenue	2.2B	1.9B	2.3B	2.5B	2.3B
Cost Of Revenue	1.3B	1.2B	1.4B	1.4B	1.1B
+Gross Profit	928.0M	720.0M	858.0M	1.1B	1.3B
Gross Margin %	42.0%	38.3%	37.2%	43.3%	54.3%
Total Operating Cost	1.5B	1.4B	1.6B	1.7B	1.3B
Selling Expenses	32.8M	32.9M	30.7M	27.9M	26.4M
Admin Expenses	144.0M	136.0M	144.0M	112.0M	104.0M
Rd Expenses	104.0M	112.0M	89.5M	58.9M	49.4M
Finance Expenses	-110.0M	-102.0M	-90.6M	36.3M	87.3M
+Operating Income	774.0M	562.0M	726.0M	877.0M	1.1B
Operating Margin %	35.0%	29.9%	31.5%	34.8%	45.7%
Non Operating Income	1.1M	6.0M	3.2M	1.2M	98,000
Non Operating Expenses	3.6M	3.1M	3.1M	4.6M	6.9M
Investment Income	5.4M	2.1M	6.6M	-2.3M	8.4M
Fair Value Change Income	2.2M	--	4.3M	-4.3M	--
Asset Disposal Income	1,000	--	--	--	45,000
Asset Impairment Loss	7.5M	12.4M	4.2M	558,600	528,300
Other Income	43.3M	47.6M	53.4M	58.2M	84.3M
Income Before Tax	772.0M	565.0M	726.0M	873.0M	1.0B
Income Tax	121.0M	89.3M	104.0M	129.0M	160.0M
+Net Income	651.0M	476.0M	622.0M	744.0M	887.0M
Net Margin %	29.5%	25.3%	27.0%	29.5%	38.5%
Net Income Attributable	651.0M	476.0M	622.0M	744.0M	887.0M
Eps Basic	1.49	1.09	1.51	1.89	2.25
Eps Diluted	1.49	1.09	1.51	1.89	2.25

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	1.1B	2.3B	2.1B	717.0M	1.0B
Trading Financial Assets	482.0M	--	230.0M	--	--
Accounts Receivable	289.0M	228.0M	259.0M	333.0M	211.0M
Notes Receivable	116.0M	53.3M	80.8M	79.4M	49.1M
Notes And Accounts Receivable	405.0M	281.0M	340.0M	412.0M	260.0M
Prepayments	19.3M	22.1M	12.0M	16.0M	7.3M
Inventory	589.0M	479.0M	471.0M	406.0M	330.0M
Total Current Assets	2.7B	3.1B	3.2B	1.6B	1.6B
Long Term Equity Investment	--	25,100	404,800	--	--
Fixed Assets	--	1.2B	1.2B	1.1B	956.0M
Fixed Assets Total	1.5B	1.2B	1.2B	1.1B	956.0M
Construction In Progress	--	353.0M	82.6M	34.8M	125.0M
Construction In Progress Total	1.1B	435.0M	123.0M	51.7M	138.0M
Intangible Assets	188.0M	192.0M	110.0M	112.0M	71.9M
Long Term Deferred Expenses	9.6M	11.0M	12.4M	4.0M	7.1M
Total Non Current Assets	2.9B	2.0B	1.5B	1.4B	1.3B
Total Assets	5.6B	5.1B	4.7B	3.0B	2.9B
Short Term Borrowings	16.1M	100.0M	--	300.0M	300.0M
Accounts Payable	250.0M	127.0M	109.0M	91.2M	127.0M
Advance Receipts	--	--	--	--	--
Contract Liabilities	24.0M	21.1M	23.3M	19.7M	27.3M
Total Current Liabilities	510.0M	461.0M	311.0M	677.0M	1.5B
Long Term Borrowings	117.0M	--	--	26.0M	40.1M
Total Non Current Liabilities	478.0M	396.0M	311.0M	367.0M	265.0M
Total Liabilities	987.0M	857.0M	622.0M	1.0B	1.8B
Paid In Capital	438.0M	438.0M	438.0M	394.0M	394.0M
Capital Reserve	2.0B	2.0B	2.0B	494.0M	484.0M
Surplus Reserve	219.0M	219.0M	219.0M	197.0M	197.0M
Retained Earnings	2.0B	1.6B	1.4B	824.0M	80.2M
Equity Attributable	4.6B	4.2B	4.1B	1.9B	1.2B
Total Equity	4.6B	4.2B	4.1B	1.9B	1.2B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	2.0B	1.7B	2.2B	2.2B	2.1B
Tax Refunds Received	44.6M	71.2M	66.9M	43.2M	22.1M
Total Operating Cash Inflow	2.1B	2.0B	2.3B	2.4B	2.4B
Cash Paid For Goods	944.0M	722.0M	1.1B	1.1B	656.0M
Cash Paid To Employees	407.0M	381.0M	370.0M	313.0M	276.0M
Taxes Paid	175.0M	126.0M	193.0M	158.0M	211.0M
Total Operating Cash Outflow	1.6B	1.3B	1.7B	1.6B	1.2B
Operating Cash Flow	500.0M	729.0M	607.0M	819.0M	1.2B
Total Investing Cash Inflow	1.8B	2.0B	1.4B	3.6B	2.0B
Total Investing Cash Outflow	3.3B	2.3B	1.9B	3.8B	2.3B
Investing Cash Flow	-1.5B	-303.0M	-455.0M	-240.0M	-297.0M
Cash From Borrowings	297.0M	100.0M	90.0M	300.0M	370.0M
Dividends And Interest Paid	220.0M	312.0M	6.8M	878.0M	853.0M
Debt Repayments	269.0M	--	430.0M	305.0M	345.0M
Total Financing Cash Inflow	312.0M	100.0M	1.6B	300.0M	370.0M
Total Financing Cash Outflow	553.0M	316.0M	467.0M	1.2B	1.2B
Financing Cash Flow	-240.0M	-216.0M	1.2B	-886.0M	-829.0M
Net Change In Cash	-1.2B	238.0M	1.4B	-327.0M	-30.8M
Ending Cash Balance	1.1B	2.3B	2.1B	692.0M	1.0B
Capex	1.1B	536.0M	260.0M	216.0M	303.0M